When a sponsor hires a full-service Contract Research Organization (CRO) — ICON, IQVIA, Parexel, PPD (part of Thermo Fisher), Labcorp Drug Development, and similar organizations are the largest examples — the site does not simply trade one monitor for another. Full-service outsourcing changes who a coordinator talks to, which functions happen at the site versus in a centralized team the site never meets, and how escalations move when something needs sponsor-level attention. This guide covers that experience from the site’s side: what to expect operationally, not the sponsor’s rationale for outsourcing in the first place.
For the underlying process of monitoring itself — visit types, source data verification, and how a monitoring plan is scoped — see Clinical Trial Monitoring: Visit Types, Source Data Verification & the Monitoring Plan, which this guide assumes as background rather than repeats. For the sponsor-side decision between running a trial in-house, through a full-service CRO, or through a functional service provider (FSP), see Clinical Trial Outsourcing: In-House vs. Full-Service CRO vs. FSP. For a sector-level view of the CRO industry, see Pharmaceutical CRO Industry: A Sector Overview.
A note on ICON specifically
This guide uses ICON plc as a representative example of a full-service CRO because it is one of the largest global CROs, publicly describing itself as providing outsourced clinical development, monitoring, and data solutions to pharmaceutical, biotechnology, and medical device sponsors across all trial phases. ICON’s own public materials describe its clinical monitoring offering as built around flexible monitoring models that adapt to a trial’s risk profile, site needs, and patient pathways, with CRAs equipped with mobile tools and trained on an ongoing basis. Where this guide describes something as specific to ICON, it is limited to what ICON discloses publicly about its service model; ICON does not publish its internal SOPs, and this guide does not claim knowledge of them. Everywhere else, what follows describes the general full-service CRO monitoring model — practices that are common across large CROs (ICON, IQVIA, Parexel, and others) because they are shaped by the same regulatory framework (ICH E6(R2)) and industry conventions, not because any one CRO’s internal process has been disclosed. A given study’s actual monitoring plan, contact structure, and system stack always governs over any general description here — always confirm against your site’s specific monitoring plan and CRO/sponsor contact list.
Visit cadence in an outsourced engagement
The visit-type sequence itself does not change because monitoring is outsourced — a full-service CRO’s CRAs still run the same lifecycle covered in the monitoring process guide: a pre-study/site selection visit, a site initiation visit (SIV), routine or interim monitoring visits at intervals set by the trial’s monitoring plan, and a close-out visit. What changes is who performs it and how consistently. A few things are worth expecting specifically in a full-service CRO engagement:
- One primary CRA per site, but not necessarily for the life of the study. Full-service CROs typically assign a lead CRA (sometimes called a Clinical Research Associate or Site Manager) as the site’s day-to-day monitoring contact. Because CRAs at large CROs are frequently reassigned across studies, sites should expect the possibility of a CRA transition mid-study and should ask, at handover, for a documented transition (a call or joint visit, not just an email introducing a new name).
- Visit scheduling runs through the CRO, not the sponsor directly. Scheduling, visit confirmation letters, and pre-visit document requests typically come from the CRA or a CRO-side clinical trial associate (CTA)/site manager, not from sponsor staff. Sites that also work directly with sponsor-run (non-outsourced) trials will notice this is the main day-to-day difference: correspondence carries the CRO’s name and systems, with the sponsor visible mainly in the protocol, the informed consent form, and periodic sponsor oversight touchpoints rather than routine scheduling.
- Interim/routine visit frequency is set by the monitoring plan, not a fixed rule. ICH E6(R2) does not mandate a fixed interval, and full-service CROs commonly apply a risk-based approach — see the central-monitoring section below — so visit frequency can vary by site based on enrollment volume, query rate, protocol complexity, and prior finding history rather than following an identical calendar across every site in the trial.
Communication channels site staff should expect
The practical day-to-day question for a coordinator is usually not what happens at a monitoring visit but who do I actually contact, and through what system, when something comes up. In a full-service CRO engagement, expect a layered structure:
The CRA as first point of contact
The assigned CRA is normally the first and primary contact for protocol questions, visit scheduling, source document queries tied to a specific visit, and day-to-day monitoring logistics. Most full-service CROs provide the CRA’s direct phone/email at site activation and expect it to be used for study-specific questions before anything is escalated further.
A defined escalation path above the CRA
Above the CRA, sites should expect a named backup or line manager — commonly titled Clinical Team Lead, Lead CRA, or Clinical Trial Manager (CTM) at the CRO — for situations the CRA cannot resolve alone: disputed findings, timeline conflicts, or anything touching site payment or contract terms. Serious issues (a safety signal, a suspected GCP deviation, a data integrity concern) should also have a documented sponsor-facing escalation path even in a fully outsourced model, because delegating monitoring to a CRO does not transfer the sponsor’s ultimate responsibility for trial oversight under ICH E6(R2) Section 5.2 — see Clinical Trial Vendor Management for the sponsor-side version of that same principle. A site’s monitoring plan or site initiation packet should specify who that sponsor-facing contact is, even when routine communication runs through the CRO.
Systems: CTMS, eTMF, and study portals
Full-service CRO engagements typically route site-facing logistics through one or more platforms rather than ad hoc email:
- A Clinical Trial Management System (CTMS) — often the CRO’s own instance, sometimes the sponsor’s — used to schedule visits, track site status and open action items, and log monitoring visit metrics. Sites are frequently given limited portal access to see upcoming visit dates and outstanding items rather than relying solely on email.
- An electronic Trial Master File (eTMF) where sites upload or the monitor files essential regulatory documents (delegation logs, training records, IRB/ethics approvals) and where document currency is tracked between visits.
- The study’s Electronic Data Capture (EDC) system, where data queries are raised and tracked — separate from the CTMS/eTMF but often cross-referenced during a monitoring visit.
Because these systems typically belong to the CRO (or are configured and administered by the CRO on the sponsor’s behalf), expect the CRO — not the sponsor — to be the point of contact for portal access issues, password resets, and system training at site activation.
Visit follow-up letters and reports
After each on-site or remote monitoring visit, expect a formal follow-up communication — commonly called a monitoring visit report, trip report, or confirmation/follow-up letter — summarizing what was reviewed, findings, and outstanding action items with target resolution dates. In a CRO-run trial this typically comes from the CRA on CRO letterhead/branding rather than the sponsor’s, though the underlying obligation to respond and close action items is the same as it would be in a sponsor-run trial. See Monitoring Visit Trip Report Writing for how these reports are structured from the monitor’s side — useful context for reading one, not just writing one.
What’s centralized at the CRO vs. handled at the site
One of the more significant practical differences in a full-service engagement is how much of the oversight function a site never sees directly, because it happens centrally across the whole trial rather than site by site. ICH E6(R2) Section 5.18.3 explicitly recognizes this model, describing centralized monitoring as a remote evaluation of accumulating data, performed in a timely manner, supported by appropriately qualified and trained persons such as data managers and biostatisticians. Full-service CROs, which run data management, biostatistics, and safety functions in-house for the studies they’re contracted on, are typically the organizations best positioned to run this centrally rather than site-by-site. For a fuller treatment of the methodology, see Risk-Based Quality Management (RBQM) in Clinical Trials.
| Typically centralized at the CRO | Typically handled at the site |
|---|---|
| Cross-site data trend analysis, statistical outlier and anomaly detection (central/risk-based monitoring) | Source data creation and maintenance for that site’s own participants |
| Data management: query generation logic, database lock activities, edit-check programming | Query response — sites still resolve queries raised against their own data, on a turnaround timeline set by the monitoring/data management plan |
| Pharmacovigilance/safety case processing and aggregate safety signal review across the trial | Individual adverse event identification, initial documentation, and expedited reporting of events at that site within protocol-required timelines |
| Risk indicator dashboards and site risk scoring used to set visit frequency and focus | Regulatory binder/eTMF document currency for that site (delegation log, training records, ethics approvals) |
| CTMS/eTMF platform administration, user access provisioning | Investigational product accountability, storage, and dispensing logs at the site |
The practical implication: a site coordinator working with a full-service CRO should expect to interact heavily with the assigned CRA for anything site-specific, but should not expect visibility into cross-site risk scoring or centralized data trend analysis — that layer exists at the CRO and typically only surfaces at the site level as a change in visit frequency, a targeted data request, or a specific query, not as a report the site sees directly.
Practical expectations for site staff
Source data and document readiness
Because interim visit frequency in a risk-based, centrally-monitored trial can shift based on centralized findings rather than a fixed calendar, sites should treat source documentation as something that needs to be visit-ready on an ongoing basis rather than only before a scheduled visit — a site that keeps source current and delegation/training logs up to date is less likely to trigger an unscheduled or more frequent visit driven by a centralized risk signal.
Query resolution turnaround
Full-service CRO data management teams typically set (and track, via the CTMS or EDC’s own metrics) a target turnaround time for query resolution — commonly in the range of several business days to two weeks depending on the sponsor’s data management plan, though the specific target is study-specific and should be confirmed in the site’s monitoring or data management plan rather than assumed. Persistently slow query resolution is one of the more common inputs into a centralized risk score, which in turn can drive an unscheduled visit or an escalation from the CRA’s line manager.
Escalation practice
Sites should know, before the first patient is enrolled, three things: who their CRA is and how to reach them, who that CRA’s backup/manager is for issues the CRA can’t resolve, and what the sponsor-facing escalation path is for anything serious enough to require it (safety concerns, suspected GCP deviations, disputes over findings). This is normally documented in the site initiation packet or the monitoring plan; if it isn’t provided proactively, it’s a reasonable thing for a coordinator to ask for at the site initiation visit rather than discover only when it’s needed.
Frequently asked questions
Does outsourcing monitoring to a CRO change the visit types a site goes through?
No — the underlying lifecycle (site selection, initiation, routine/interim monitoring, close-out) is set by the trial’s protocol and monitoring plan, not by who performs it. What changes is who conducts the visits, what systems and branding site staff interact with, and how centralized functions like risk scoring and data management are organized. See Clinical Trial Monitoring: Visit Types, Source Data Verification & the Monitoring Plan for the visit-type detail.
If the CRO runs monitoring, is the sponsor still responsible for trial oversight?
Yes. Under ICH E6(R2) Section 5.2, a sponsor may transfer trial-related duties to a CRO, but ultimate responsibility for the quality and integrity of the trial’s data remains with the sponsor. A full-service CRO engagement should still have a defined sponsor-facing escalation path for issues serious enough to require it, even though routine monitoring communication runs through the CRO.
Is ICON’s monitoring process different from other full-service CROs like IQVIA or Parexel?
Publicly, large full-service CROs describe broadly similar service models — risk-adapted or risk-based monitoring, CRA teams supported by centralized data management and biostatistics, and CTMS/eTMF-based site communication — because they operate under the same ICH E6(R2) framework and serve the same sponsor base. Specific internal SOPs, staffing ratios, and system configurations are not typically published by any CRO, including ICON, and vary by contract and study; a site’s actual experience is governed by that specific trial’s monitoring plan, not by a CRO’s general public description of its capabilities.
Who provides CTMS or eTMF portal access to site staff in an outsourced trial?
In most full-service CRO engagements, the CRO administers and provisions access to the study’s CTMS and eTMF (whether it is the CRO’s own platform or the sponsor’s, configured by the CRO), so portal access issues and training are typically directed to the CRO’s site-facing team rather than the sponsor.
See also: How to Select a Clinical Trial Management System (CTMS): A Buyer’s Guide, What Does a Clinical Research Coordinator Do?, and Contract Research Organization (CRO).
